A controlled study of the effect on airflow obstruction of 30 mg of the alphablocker thymoxamine given by inhalation is reported in 10 patients with chronic stable asthma. No significant change in peak expiratory flow rate. was seen with either thymoxamine or placebo in any patient. Alpha-adrenergic receptors are therefore unlikely to contribute significantly to resting bronchomotor tone in chronic stable asthma.
Introduction
Alpha-agonists can produce bronchial smooth muscle contraction in patients with asthma, and this effect can be inhibited by the alpha-blocker thymoxamine (Patel 1979) . When given by inhalation, thymoxamine has also been seen to protect against exercise-induced bronchospasm (Patel 1979) . The present study was designed to investigate the clinical effectiveness of inhaled thymoxamine in patients with chronic stable asthma.
Patients and methods
Ten patients with chronic stable asthma were studied, 6 female and 4 male, mean age 33 years (range 20-68). Eight patients had positive skin tests. All were taking regular inhaled salbutamol, 7 were taking inhaled steroids and one patient was taking a slow-release aminophylline preparation. Each patient was studied on two separate days. Inhaled bronchodilators were omitted on the day of investigation, and long-acting bronchodilators for 24 hours prior to investigation. Baseline peak expiratory flow rate (PEFR), using a Wright's peak flow meter, was taken as the mean of six readings. Baseline PEFR values on each study day were within 20% of each other in all patients. On the first day of study the patient was given an inhalation of 2 ml of a 1.5% solution of thymoxamine in water (equivalent to 30mg of thymoxa mine), or 2 ml water as a control in a single blind randomized fashion from a Wright's nebulizer. Two PEFR readings were taken immediately after the inhalation, and then at five minute intervals for 60 minutes. The average of the two readings was taken as the value for subsequent analysis. On the second day the procedure was repeated with water or thymoxamine as appropriate.
Results
The mean change in PEFR from baseline over the 60 minutes of the study was calculated for each patient, and expressed in absolute and in percentage terms (Table I) . This value is directly proportional to the area under the curve. There were no significant changes in PEFR from baseline for either placebo or thymoxamine (paired t test and Wilcoxon Rank Sum Test) (Table I) . Two patients increased their PEFR by more than 10% after thymoxamine, but one of these showed a similar rise with placebo. In one patient, PEFR fell markedly after thymoxamine. No subjective improvement was reported after thymoxamine. 
Discussion
Alpha-agonists can produce bronchial smooth muscle contraction in patients with asthma (Patel 1979) , but this effect is not demonstrable in normal subjects either in vivo (Anthracite et al. 1977 , Snashall et al. 1978 or in vitro (Simonsson et al. 1972 , Kneussl & Richardson 1978 . In patients with. asthma thymoxamine inhibits this alpha effect, which suggests that there may be a relative imbalance of alpha-and beta-receptors in patients with asthma. Henderson et al. (1979) have demonstrated this to be so for vascular and pupillary smooth muscle receptors in man, and Barnes et al. (1980) have shown increased alpha-and fewer betareceptors in pulmonary homogenates of an animal model of asthma. Patel et al. (1976) showed that thymoxamine by inhalation partly protects against exerciseinduced bronchospasm, although Sly et al. (1967) reported no inhibition of post-exercise bronchospasm after intravenous phentolamine. Thymoxamine given orally in normal volunteers (Bianco et al. 1972) or intravenously in patients with asthma (Gaddie et al. 1972) significantly reduces histamine-induced bronchospasm.
Our data suggest that bronchial muscle tone as measured by PEFR is not significantly dependent on alpha-adrenergic activity. It may be the case, however, that at rest, irrespective of whether or not a subject has asthma, circulating catecholamine levels are low and bronchial smooth muscle tone is predominantly dependent on other mediator systems. With exercise the sudden release of noradrenaline from the adrenal medulla (Beil et al. 1977 ) may render the bronchial muscle adrenoceptor system dominant, with subsequent dilatation or constriction according to the relative numbers and sensitivity of beta-and alpha-receptors. The predominance of alpha-receptors in patients with asthma would thus result in overall bronchoconstriction ( Figure I) , which would explain the effectiveness of thymoxamine in reducing the degree of exercise-induced bronchospasm in patients with asthma (Patel et al. 1976) . Beta-responsiveness is diminished in patients with asthma (Szentivanyi 1968 ) and so it can be hypothesized that, if beta-responsiveness becomes even less during an acute attack of asthma, alpha-blockade may then be clinically useful. 
